Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

dual tasking

- PMLiVE

GSK’s RSV vaccine Arexvy recommended by CHMP for adults aged 50 to 59 years

The positive opinion comes just over a year after Arexvy was approved for those aged 60 and over

- PMLiVE

BioNTech shares promising results for mRNA immunotherapy candidate in advanced melanoma

Melanoma is currently responsible for around 58,000 deaths globally every year

- PMLiVE

Making space to amplify impact

The pharma innovator’s strategic summer resolution

- PMLiVE

The importance of being earnest: supporting healthcare professionals in guiding patients through their journey

How can clinicians tell patients what they need to understand in a way that is accessible, useful, and actionable?

Mednet

- PMLiVE

GSK and Flagship Pioneering partner in deal worth up to $7bn to discover medicines and vaccines

The companies aim to develop a portfolio of up to ten candidates

- PMLiVE

Johnson & Johnson’s Darzalex Faspro regimen approved by FDA for multiple myeloma

More than 35,000 new cases of the blood cancer are expected to be diagnosed in the US this year

- PMLiVE

Boehringer Ingelheim’s Spevigo recommended by CHMP for generalised pustular psoriasis

The chronic neutrophilic inflammatory disease can lead to severe complications, including multisystem organ failure

Biogen Idec building

Biogen/Eisai’s Alzheimer’s drug shows continued cognitive improvement in long-term study

Leqembi was granted traditional US approval last year to treat patients in the early stages of the disease

- PMLiVE

Merck and Astellas/Pfizer’s bladder cancer combination receives positive CHMP opinion

More than 165,000 new cases of bladder cancer are diagnosed in the EU every year

- PMLiVE

What’s the difference?

What value does your strategic planning add?

- PMLiVE

Boehringer Ingelheim expands immuno-oncology pipeline with $1.3bn Nerio acquisition

The deal gives the company access to a preclinical immune checkpoint inhibitor programme

- PMLiVE

FDA approves Sun Pharma’s oral JAK inhibitor Leqselvi to treat severe alopecia areata

The autoimmune disease currently affects around 700,000 people in the US

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links